Table 2.
Association between aMED, sleep disorder and mortality
| Unadjusted | Model I | Model II | Model III | |||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| All-cause mortality | ||||||||
| Higher aMED | Reference | |||||||
| Median aMED | 1.25 (1.10–1.44) | 0.001 | 1.49 (1.30–1.71) | < 0.0001 | 1.35 (1.16–1.57) | 0.0001 | 1.36 (1.14–1.63) | 0.0006 |
| Lower aMED | 1.50 (1.32–1.69) | < 0.0001 | 1.77 (1.58–1.98) | < 0.0001 | 1.45 (1.27–1.66) | < 0.0001 | 1.42 (1.20–1.67) | < 0.0001 |
| aMED(continuous) | 1.12 (1.08–1.16) | < 0.0001 | 1.18 (1.15–1.22) | < 0.0001 | 1.11 (1.07–1.15) | < 0.0001 | 1.09 (1.04–1.15) | 0.0005 |
| Sleep disorder* | 1.63 (1.39–1.91) | < 0.0001 | 1.41 (1.21–1.63) | < 0.0001 | 1.49 (1.26–1.75) | < 0.0001 | 1.42 (1.15–1.75) | 0.0011 |
| CVD mortality | ||||||||
| Higher aMED | Reference | |||||||
| Median aMED | 1.19 (0.95–1.49) | 0.1275 | 1.44 (1.14–1.82) | 0.0025 | 1.27 (0.98–1.66) | 0.0703 | 1.05 (0.94–1.50) | 0.1023 |
| Lower aMED | 1.35 (1.07–1.70) | 0.0107 | 1.59 (1.27-2.00) | < 0.0001 | 1.28 (1.05–1.65) | 0.0321 | 1.13 (1.05–1.51) | 0.0422 |
| aMED(continuous) | 1.10 (1.03–1.18) | 0.0035 | 1.17 (1.09–1.25) | < 0.0001 | 1.09 (1.01–1.17) | 0.0341 | 0.99 (0.85–1.15) | 0.8960 |
| Sleep disorder* | 1.84 (1.34–2.51) | 0.0001 | 1.66 (1.22–2.27) | 0.0013 | 1.83 (1.36–2.47) | < 0.0001 | 1.61 (1.10–2.35) | 0.0148 |
| Cancer mortality | ||||||||
| Higher aMED | Reference | |||||||
| Median aMED | 0.99 (0.68–1.43) | 0.9377 | 1.16 (0.81–1.66) | 0.427 | 1.07 (0.73–1.56) | 0.7411 | 1.32 (0.79–2.21) | 0.29 |
| Lower aMED | 1.16 (0.91–1.47) | 0.2457 | 1.35 (1.07–1.72) | 0.0132 | 1.20 (0.93–1.55) | 0.1713 | 1.21 (0.78–1.87) | 0.3947 |
| aMED(continuous) | 1.04 (0.99–1.11) | 0.1424 | 1.10 (1.04–1.17) | 0.0007 | 1.06 (0.99–1.13) | 0.0920 | 1.07 (0.96–1.19) | 0.2454 |
| Sleep disorder* | 1.11 (0.79–1.55) | 0.5493 | 0.93 (0.67–1.30) | 0.6736 | 0.98 (0.69–1.39) | 0.9166 | 1.04 (0.64–1.68) | 0.8804 |
CVD, cardiovascular disease; Model I initially was adjusted for age, sex, and race (Mexican American, non-Hispanic white, non-Hispanic black, other races); model II was further adjusted for education level (below high school, high school or equivalent, college or above), marital status (married, widowed, divorced, and never married), and family PIR based on model I; model III further adjusted for BMI, smoking status, total energy intake, comorbidities including diabetes mellitus, hypertension, CHF, CHD, and stroke. *No sleep disorder was set as the reference group